SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-006752
Filing Date
2020-05-15
Accepted
2020-05-15 16:51:36
Documents
76
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20200331x10q.htm 10-Q 2104549
2 EX-31.1 otlk-20200331ex311bb889a.htm EX-31.1 13679
3 EX-32.1 otlk-20200331ex321a85855.htm EX-32.1 9110
  Complete submission text file 0001558370-20-006752.txt   8067166

Data Files

Seq Description Document Type Size
4 EX-101.INS otlk-20200331.xml EX-101.INS 1676507
5 EX-101.SCH otlk-20200331.xsd EX-101.SCH 58664
6 EX-101.CAL otlk-20200331_cal.xml EX-101.CAL 62882
7 EX-101.DEF otlk-20200331_def.xml EX-101.DEF 240370
8 EX-101.LAB otlk-20200331_lab.xml EX-101.LAB 477575
9 EX-101.PRE otlk-20200331_pre.xml EX-101.PRE 446392
Mailing Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852
Business Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 20886330
SIC: 2836 Biological Products, (No Diagnostic Substances)